Cambodia vs Pre-demographic dividend: Antiretroviral therapy coverage
Cambodia
92.0%
in 2024
Pre-demographic dividend
82.2%
in 2024
Cambodia rank
14th
Pre-demographic dividend rank
11th
Antiretroviral therapy coverage over time
- Cambodia
- Pre-demographic dividend
How they compare
Cambodia currently reports 92.0% against 82.2% in Pre-demographic dividend, a difference of 9.8%.
That makes Cambodia's figure about 1.1 times Pre-demographic dividend's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Pre-demographic dividend ahead.
Cambodia ranks 14th and Pre-demographic dividend ranks 11th of 143 countries.
Cambodia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cambodia | Pre-demographic dividend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 15.6% | 5.1% | 10.5% | Cambodia |
| 2010s | 64.6% | 41.8% | 22.8% | Cambodia |
| 2020s | 85.2% | 74.6% | 10.6% | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Cambodia or Pre-demographic dividend?
- Cambodia, at 92.0% against 82.2% in Pre-demographic dividend as of 2024.
- What is the difference in antiretroviral therapy coverage between Cambodia and Pre-demographic dividend?
- 9.8%, with Cambodia ahead.
- How many years of comparable data are there for Cambodia and Pre-demographic dividend?
- 25 years are reported by both, from 2000 to 2024.
- How do Cambodia and Pre-demographic dividend rank globally for antiretroviral therapy coverage?
- Cambodia ranks 14th and Pre-demographic dividend ranks 11th of 143 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.